MYX2470 / Myricx Pharma - LARVOL DELTA

Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients (Novartis Press Release) - "Myricx is developing two lead assets directed towards the targets B7-H3 and HER2, with potential across multiple solid tumor settings....Under the terms of the agreement, Novartis will pay USD 1.1bn upfront, with up to USD 400m in potential milestone payments to acquire Myricx Bio. The transaction is expected to close in H2 2026, subject to the satisfaction or waiver of customary closing conditions, including regulatory approvals."

M&A • Breast Cancer • Gastric Cancer • Prostate Cancer

Francis Crick and ICL spinout raises £90m to clinically develop cancer treatments (PharmaTimes) - "The Francis Crick Institute and Imperial College London (ICL) cancer therapy spinout, Myricx Bio, has raised £90m in series A financing to advance its novel cancer treatments into clinical development...The investment will help to develop the company’s therapies to treat a range of different tumour types, including breast, lung and colorectal cancer, to advance into clinical testing...The spinout is focused on the discovery and development of a novel class of payloads for antibody-drug conjugates..."

Financing • Breast Cancer • Colorectal Cancer • Lung Cancer

Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics (GlobeNewswire) - "Myricx Bio...today announce that they have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on WuXi Bio’s integrated technology platforms. Under the terms of the agreement, Myricx will develop the antibody into a first-in-class ADC based on its NMTi payload platform...including microtubule and topoisomerase inhibitors. Myricx intends to progress the ADC through preclinical and clinical development for difficult-to-treat solid tumours. WuXi Bio will receive an upfront payment and will be eligible for development and commercialisation milestone payments, as well as royalties on net sales."

Licensing / partnership • Solid Tumor

Myricx Bio to Present Preclinical Data Validating NMTi as a Novel ADC Payload Class (GlobeNewswire) - "Myricx Bio...is presenting preclinical in vivo efficacy data for its NMTi-ADC platform and pipeline at the 14th Annual World ADC Event, San Diego, California, held from October 16-19, 2023....In the poster presentation Myricx reported data for three NMTi-ADCs in its pipeline. These comprise B7-H3-NMTi, TROP2-NMTi, and HER2-NMTi. B7-H3-NMTi demonstrated complete and durable tumour regressions in multiple models of aggressive prostate cancer refractory to Topo1i-based ADCs....TROP2-NMTi also demonstrated complete and durable tumour regressions in breast cancer models refractory to Topo1i-based ADCs; including the ability to regress large and established tumours that had prior exposure to a Topo1i-based ADC. HER2-NMTi demonstrated complete efficacy, and an encouraging tolerability profile in rodents and non-human primates."

Preclinical • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor